Home  |  Top News  |  Most Popular  |  Video  |  Multimedia  |  News Feeds  |  Feedback
  Medicine  |  Nature & Earth  |  Biology  |  Technology & Engineering  |  Space & Planetary  |  Psychology  |  Physics & Chemistry  |  Economics  |  Archaeology
Top > Medicine, Health Care > Stroke Drug Kills Bacteria That… >

Stroke Drug Kills Bacteria That Cause Ulcers And Tuberculosis

Published: December 20, 2012.
Released by Federation of American Societies for Experimental Biology  

Bethesda, MD—A drug currently being used to treat ischemic strokes may prove to be a significant advance in the treatment of tuberculosis and ulcers. In a new research report appearing online in The FASEB Journal, a compound called ebselen effectively inhibits the thioredoxin reductase system in a wide variety of bacteria, including Helicobacter pylori which causes gastric ulcers and Mycobacterium tuberculosis which causes tuberculosis. Thioredoxin and thioredoxin reductase proteins are essential for bacteria to make new DNA, and protect them against oxidative stress caused by the immune system. Targeting this system with ebselen, and others compounds like it, represents a new approach toward eradicating these bacteria.

"This new antibacterial principle provides better chances of surviving an infection," said Arne Holmgren, M.D., Ph.D., a researcher involved in the work from the Division of Biochemistry in the Department of Medical Biochemistry and Biophysics, at Karolinska Institutet in Stockholm, Sweden. "Since ebselen is also an antioxidant, the present mechanism can be described as a 'two for the price of one' antioxidant action in inflammation, and specific targeting of multi-resistant bacterial complications and sepsis."

Building on previous observations where ebselen has shown antibacterial properties against some bacteria, Holmgren and colleagues hypothesized that the bacteria sensitive to ebselen relied solely on thioredoxin and thioredoxin reductase for essential cellular processes. They investigated this by testing it on strains of E. coli with deletions in the genes for thioredoxin, thioredoxin reductase and the glutaredoxin system. They found that strains with deletions in the genes coding for glutaredoxin system were much more sensitive than normal bacteria. Researchers further tested ebselen against Helicobacter pylori and Mycobacterium tuberculosis, which both naturally lack the glutaredoxin system and are frequently resistant to many commonly used antibiotics, and found both to be sensitive to ebselen.

"As rapidly as these organisms evolve, we need new drugs sooner rather than later," said Gerald Weissmann, M.D., Editor-in-Chief of The FASEB Journal. "The fact that these scientists have found a new target for killing some of the most resistant bacteria is great news, but the fact that we already have at least one drug which we could possibly use now makes the news even better."




The above story is based on materials provided by Federation of American Societies for Experimental Biology.

Translate this page: Chinese French German Italian Japanese Korean Portuguese Russian Spanish


comments powered by Disqus


Related »

Nizet 
6/10/15 

Common Antibiotic May Be the Answer to Many Multidrug-resistant Bacterial Infections
Baumannii 
9/15/12 
Discovery of Essential Genes for Drug-resistant Bacteria Reveals New, High-value Drug Targets
BUFFALO, N.Y. -- Biomedical scientists collaborating on translational research at two Buffalo institutions are reporting the discovery of a …
Strain 
1/31/12 
Exposure to Common Environmental Bacteria May Be Source of Some Allergic Inflammation
Could some cases of asthma actually be caused by an allergic reaction to a common environmental bacteria? New research …
Jaenike 
7/8/10 
New Way to Conquer Disease-causing Nematodes in Flies Has Implications for Human Diseases
A Science article published on July 9, 2010, describes the discovery of an alternative form of evolution that helps …
Antimicrobial 
9/26/14 
Smelly Discovery Challenges Effectiveness of Antimicrobial Textiles
Anti-odour clothing may not be living up to its promise, and an ALES researcher is saying it could all …
More » 
 
© Newsline Foundation  |  About  |  Privacy Policy  |  Feedback  |  Mobile